Notice2022-03629
Notice of Award of a Single-Source Cooperative Agreement To Fund the Kazakhstan Scientific Center for Dermatology and Infectious Diseases (KSCDID)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 22, 2022
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $500,000, for Year 1 of funding to the Kazakhstan Scientific Center for Dermatology and Infectious Diseases (KSCDID). The award will reduce new HIV infections and AIDS deaths in Kazakhstan through rapidly expanding prevention, testing, care, and effective treatment services to people living with HIV (PLHIV). Funding amounts for years 2-5 will be set at continuation.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 35 (Tuesday, February 22, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 35 (Tuesday, February 22, 2022)]
[Notices]
[Page 9622]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-03629]
[[Page 9622]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
the Kazakhstan Scientific Center for Dermatology and Infectious
Diseases (KSCDID)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $500,000, for Year 1 of funding to the
Kazakhstan Scientific Center for Dermatology and Infectious Diseases
(KSCDID). The award will reduce new HIV infections and AIDS deaths in
Kazakhstan through rapidly expanding prevention, testing, care, and
effective treatment services to people living with HIV (PLHIV). Funding
amounts for years 2-5 will be set at continuation.
DATES: The period for this award will be September 30, 2022 through
September 29, 2027.
FOR FURTHER INFORMATION CONTACT: Patrick Nadol, Center for Global
Health, Centers for Disease Control and Prevention, 171 Prospect Mira,
Bishkek, 720016, Kyrgyz Republic, Telephone: 800-232-6348, E-Mail:
<a href="/cdn-cgi/l/email-protection#6c1c0902592c0f080f420b031a"><span class="__cf_email__" data-cfemail="cfbfaaa1fa8facabace1a8a0b9">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The single-source award will implement
prevention, testing, care and treatment, laboratory, and strategic
information activities in Kazakhstan. KSCDID is in a unique position to
conduct this work, as it is the leading organization implementing the
National HIV program in Kazakhstan; it will lead and sustain the
national HIV services for prevention, testing, care, treatment, and
strategic information according to international standards to achieve
epidemic control and ensure resilient and sustained health care
systems. KSCDID develops policy and regulations, conducts prevention
and testing activities, coordinates care and treatment, and is
responsible for quality assurance of laboratory services.
Summary of the Award
Recipient: Kazakhstan Scientific Center for Dermatology and
Infectious Diseases (KSCDID).
Purpose of the Award: The purpose of this award is to reduce new
HIV infections and AIDS deaths in Kazakhstan through rapidly expanding
prevention, testing, care, and effective treatment services to PLHIV.
Amount of Award: The approximate year 1 funding amount will be
$500,000 in Federal Fiscal Year (FFY) 2022 funds, subject to the
availability of funds. Funding amounts for years 2-5 will be set at
continuation.
Authority: This program is authorized under Public Law 108-25 (the
United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act
of 2003).
Period of Performance: September 30, 2022 through September 29,
2027.
Dated: February 15, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2022-03629 Filed 2-18-22; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 22, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.